2023 ASCO | Phase I Trial of Chimeric Anti-GPC3 scFv-CD3ε Engineered T Cells (CT0180) in Patients with Advanced Hepatocellular Carcinoma

2023 AACR | CLDN18.2 expression is associated with clinicopathological features and prognosis of Chinese patients with digestive system cancers: a retrospective analysis

2023 ASCO GI | A Multicenter, Phase 1 Study of AB011, a Recombinant Humanized Anti CLDN18.2 Monoclonal Antibody (AB011), as Monotherapy and Combined with Capecitabine and Oxaliplatin (CAPOX) in Patients with Advanced Solid Tumors

2022 ASH | Phase II Study of Fully Human BCMA-Targeted CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

2022 CAR TCR Summit

2022 ASCO | Safety, Tolerability and Preliminary Efficacy Results in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma from a Phase Ib/II Study of CLDN18.2 CAR T‐cell therapy (CT041)